{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:25:06Z","timestamp":1777425906833,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Validate the Treatment Adherence Measure (TAM) instrument in outpatients with MM concerning construct validity, reliability and the ceiling and floor effects.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This cross-sectional study included patients diagnosed with MM previously treated with an immunomodulator for at least one month, aged 18 or over, and followed-up in the investigated outpatient clinics. Adherence to immunomodulators was measured by TAM. The TAM\u2019s reliability was assessed using Cronbach\u2019s alpha; The association between adherence and health-related quality of life was investigated to analyze the divergent and convergent construct, measured by the Quality of Life Questionnaire core (QLQ-C30) and the Quality of Life Questionnaire Multiple Myeloma module (QLQ-MY20). The presence of a ceiling or floor effect in the TAM was also analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Eighty-four patients were included in the study, achieving 97.6% adherence. Cronbach\u2019s alpha was 0.41, and the hypothesis of convergent construct validity was confirmed, with statistical significance, in contrast to the hypothesis of divergent construct validity. The presence of the ceiling effect in TAM suggested that this instrument does not allow changes to be detected in individuals concerning adherence to IMiDs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> TAM instrument did not show satisfactory validity and reliability to measure MM\u2019s adherence. MM patients treated at oncohematological outpatient clinics in a metropolitan region of southeastern Brazil showed high adherence to IMiDs.<\/jats:p>","DOI":"10.3389\/fphar.2021.651523","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T05:27:52Z","timestamp":1620192472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"L\u00edvia Pena","family":"Silveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane Aparecida","family":"Menezes de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Lana de Miranda","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Soares","family":"Malta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta M\u00e1rcia","family":"Marques dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiane Lima","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta\u00edsa Roberta Lopes","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano Max Moreira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-Of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and Paradigms in Multiple Myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/0104-1169.3155.2386","article-title":"Adherence to Treatment for Diabetes Mellitus: Validation of Instruments for Oral Antidiabetics and Insulin","volume":"22","author":"Boas","year":"2014","journal-title":"Rev. Latino-am. Enfermagem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1590\/0034-7167-2017-0796","article-title":"Adaptation and Validation of the Measuring of Treatment Adherence for Mental Health","volume":"71","author":"Borba","year":"2018","journal-title":"Rev. Bras. Enferm."},{"key":"B6","article-title":"Measuring Health: A Review of Quality of Life Measure Scales","author":"Bowling","year":"2005"},{"key":"B1","article-title":"RESOLU\u00c7\u00c3O No 11, DE 22 DE MAR\u00c7O DE 2011 Disp\u00f5e sobre o controle da subst\u00e2ncia Talidomida e do medicamento que a contenha","year":"2011"},{"key":"B7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1590\/s0104-11692010000300002","article-title":"Adaptation and Validation of an Oral Anticoagulation Measurement of Treatment Adherence Instrument","volume":"18","author":"Carvalho","year":"2010","journal-title":"Rev. Latino-am. Enfermagem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/ajh.24891","article-title":"Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy","volume":"92","author":"Cho","year":"2017","journal-title":"Am. J. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0214446","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to Immunomodulatory Drugs in Patients with Multiple Myeloma","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/cam4.13410.1002\/cam4.1347","article-title":"Epidemiology of Multiple Myeloma in 17 Latin American Countries: an Update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/phar.1174","article-title":"Preliminary Validation of Self-Assessment Tool to Measure Imatinib Adherence in Patients with Chronic Myeloid Leukemia","volume":"33","author":"Daouphars","year":"2013","journal-title":"Pharmacotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/m18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"De Geest","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511996214","volume-title":"Measure in Medicine - A Practical Guide","author":"de Vet","year":"2011"},{"key":"B14","first-page":"81","article-title":"Contributo para a valida\u00e7\u00e3o concorrente de uma medida de ades\u00e3o aos tratamentos","volume":"2","author":"Delgado","year":"2001","journal-title":"Psicologia, Sa\u00fade Doen\u00e7as"},{"key":"B15","unstructured":"EORTC QLQ-C30 Scoring Manual. EORTC Quality of Life Group2001"},{"key":"B16","unstructured":"EORTC QLQ-MY20 Scoring Manual2007"},{"key":"B17","unstructured":"EORTC Quality of Life2019"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1590\/s1807-59322011001100002","article-title":"Autologous Stem Cell Transplantation Improves Quality of Life in Economically Challenged, Brazilian Multiple Myeloma Patients","volume":"66","author":"Etto","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1007\/s00520-019-04721-4","article-title":"High Adherence of Patients with Multiple Myeloma Who Receive Treatment with Immunomodulatory Drugs (IMIDS) in Hematology\/oncology Group Practices in Germany","volume":"27","author":"Feiten","year":"2019","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1590\/s1808-86942010000100014","article-title":"Propriedades psicom\u00e9tricas Do question\u00e1rio internacional: aparelho de amplifica\u00e7\u00e3o sonora individual","volume":"76","author":"Gasparin","year":"2010","journal-title":"Braz. J. Otorhinolaryngol. (Impr.)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1590\/S0104-11692009000100008","article-title":"Factors Related to Patient Adherence to Antidiabetic Drug Therapy","volume":"17","author":"Gimenes","year":"2009","journal-title":"Rev. Latino-am. Enfermagem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the Effect of Adherence on Patient-Reported Outcomes and Out of Pocket Costs Among Patients with Multiple Myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00025","article-title":"Epidemiology of Hematologic Malignancies in Real-World Settings: Findings from the Hemato-Oncology Latin America Observational Registry Study","volume":"5","author":"Hungria","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival: A Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.clml.2017.02.024","article-title":"Treating Multiple Myeloma Patients with Oral Therapies","volume":"17","author":"Kumar","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101151","DOI":"10.1016\/j.beha.2020.101151","article-title":"Modern Treatments and Future Directions for Newly Diagnosed Multiple Myeloma Patients","volume":"33","author":"Lu","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"B28","article-title":"Validity and Reliability of the QLQ-MY20 Module for Assessing the Health-Related Quality of Life in Brazilians with Multilpe Myeloma","author":"Malta","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to Oral Cancer Therapy in Older Adults: The International Society of Geriatric Oncology (SIOG) Taskforce Recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"10s","DOI":"10.11606\/s1518-8787.2018052000637","article-title":"Multimorbidity","volume":"52","author":"Nunes","year":"2018","journal-title":"Rev. Sa\u00fade P\u00fablica"},{"key":"B31","volume-title":"Psychometric Theory","author":"Nunnally","year":"1994"},{"key":"B32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1590\/s0066-782x2012005000053","article-title":"Rela\u00e7\u00e3o entre a Escala de Ades\u00e3o Terap\u00eautica de oito itens de Morisky (MMAS-8) e o controle da press\u00e3o arterial","volume":"99","author":"Oliveira-Filho","year":"2012","journal-title":"Arq. Bras. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to Medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00520-014-2206-3","article-title":"Further Evaluation of the EORTC QLQ-C30 Psychometric Properties in a Large Brazilian Cancer Patient Cohort as a Function of Their Educational Status","volume":"22","author":"Paiva","year":"2014","journal-title":"Support Care Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: a Systematic Review and Economic Evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol. Assess."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.1590\/s1518-8787.2016050006145","article-title":"Polypharmacy and Polymorbidity in Older Adults in Brazil: a Public Health Challenge","volume":"50","author":"Ramos","year":"2016","journal-title":"Rev. Sa\u00fade P\u00fablica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1590\/s0080-623420130000500012","article-title":"Impact of the Disease: Acceptability, Ceiling and Floor Effects and Reliability of an Instrument on Heart Failure","volume":"47","author":"Rodrigues","year":"2013","journal-title":"Rev. Esc. Enferm. USP"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s00520-020-05469-y","article-title":"A Review of Factors Influencing Non-adherence to Oral Antineoplastic Drugs","volume":"28","author":"Ross","year":"2020","journal-title":"Support Care Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"107815522199352","DOI":"10.1177\/1078155221993528","article-title":"Adherence to Thalidomide in Patients with Multiple Myeloma: A Cross-Sectional Study in a Brazilian Metropolis","volume":"2021","author":"Silveira","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report Measures of Medication Adherence Behavior: Recommendations on Optimal Use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Behav. Med. Pract. Pol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality Criteria Were Proposed for Measurement Properties of Health Status Questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A New Taxonomy for Describing and Defining Adherence to Medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T10:55:31Z","timestamp":1621940131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":42,"alternative-id":["10.3389\/fphar.2021.651523"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.651523","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"article-number":"651523"}}